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ABSTRACT: 
The aim of present study is to examine the in-vitro in-vivo correlation (IVIVC) of immediate 
release product. Metronidazole 500mg and its brands of immediate release dosage forms. 
Metronidazole is clearly classified into BCS class I, and could be evaluated under bio waiver 
conditions. The in vitro parameters employed were hardness, weight uniformity, friability, 
disintegration time, absolute drug content , dissolution rate (in 0.1 N Hydrochloric acid, 
phosphate buffer and acetate buffer at 37ºC),and dissolution efficiencies were also analyzed. 
The in-vitro dissolution study was performed on the brands, according to FDA,USP  dissolution 
profile in three different PH (1.2),(4.5), and (6.8) at37ºC ,using the USP apparatus II,  then f1 ,f2 
were determined for the time intervals of 10, 15, 30, 45 and 60 minutes, and dissolution 
efficiencies were calculated.  MINITAB 14 statistical programused for in vitro in vivo 
correlation, level A was done for reference product. A non linear relation was established which 
is typical for immediate release formulation, of class 1. 
 
Key words: bioavailability, bioequivalence, biopharmaceutical classification system,Bio-waiver 
correlation. 
 
 
INTRODUCTUON 
Bio-equivalence: 
Is defined as “the absence of a significant difference in the rate and extent to which the active 
ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives 
becomes available at the site of drug action when administered at the same molar dose under 
similar conditions in an appropriately designed study”. 
If two medicines are bioequivalent there is no clinically significant difference in their 
bioavailability. 
In vitro testing, preferably based on a documented "in-vitro/in-vivo correlation". May sometimes 
provide the same indication of bioequivalence between two pharmaceuticals. 
Bioequivalence is determined based on the relative bioavailability of the innovator medicine 
versus the generic medicine. It is measured by comparing the ratio of the pharmacokinetic 
variables for the innovator versus the generic medicine where equality is 1. 
Bioequivalence studies focus on the release of drug from dosage form, formulation and 
subsequent absorption into the systemic circulation. Bio-equivalence studies may involve both 
in-vivo and in-vitro studies. 
In Vivo in Vitro Correlations 
Development and optimization of formulation is an integral part of manufacturing and marketing 
of any therapeutic agent which is indeed a time consuming and costly process. Optimization 
process may require alteration in formulation composition, manufacturing process, equipment 
and batch sizes. If these types of changes are applied to a formulation, studies in human healthy 
volunteers may be required to prove that the new formulation is bioequivalent with the old one. 
Certainly, implementation of these requirements not only halts the marketing of the new 
 formulation but also increases the cost of the optimization processes. It would be, desirable, 
therefore, to develop in vitro tests that reflect bioavailability data. A regulatory guidance for both 
immediate- and modified-release dosage forms has been, therefore, developed by the FDA to 
minimize the need for bioavailability studies as part of the formulation design and optimization 
(Amidon, et.al, 1995). 
IVIVC can be used in the development of new pharmaceuticals to reduce the number of human 
studies during the formulation development. 
Correlation Definitions: 
The term correlation is frequently employed within the pharmaceutical and related sciences to 
describe the relationship that exists between variables. Mathematically, the term correlation 
means interdependence between quantitative or qualitative data or relationship between 
measurable variables and ranks (Blaskovich, et.al, 2003). From biopharmaceutical standpoint, 
correlation could be referred to as the relationship between appropriate in vitro release 
characteristics and in vivo bioavailability parameters, Two definitions of ivivc have been 
proposed by the USP and by the FDA (Chen, et.al, 2005),(Jayaprakasam,  et.al, 2003). 
 
MATERIALS AND METHODS: 
Physical Test: 
Uniformity of Weight Test. 
i. 20 randomly selected tablets were weighed. The average weights were determined. 
ii. The tablets were weighed individually and the percentage of deviation of its weight from the 
average weight was determined for each tablet . 
iii. The deviation of individual weight from the average weight should not exceed the limit given 
in table 3: 
Hardness Test. 
The hardness of 10 tablets randomly selected from each batch weredetermined on an automatic 
tablet hardness tester. The crushing strength of uncoated tablets is accepted within 4-8 kg/cm2 
Friability Test 
20 tablets previously freed of dust were weighed together beforetransferring to a frabilator set to 
run for 4 min at 25 r.p.m. Thereafter they were removed, dusted and reweighed: 
 
% Friability = [(Wi – Wf)/ Wi] x 100, (should be less than 1%) 
Where;  
 Wi is the initial weight and Wf the final weight of the tablets. 
Disintegration Time Test. 
According to official monograph determination of disintegration time for uncoated tablets was 
adopted using a disintegrating apparatus and the medium was distilled water at 37±1
o
C.six 
tablets were used for the determination. Accepted range for the uncoated tablet up to 30 mi 
Absolute drug content 
Five pre-weighed tablets were crushed; the equivalent weight of a tablet was weighed out and 
dissolved in 500 ml of 0.1M NaoH in a volumetric flask, and filtered. The absorbance reading 
was determined using UV-visible spectrophotometer at 319nm. 
In Vitro Dissolution Test 
Volume of 900 ml of each buffer was employed. Dissolution testing was performed using Tablet 
Dissolution Tester (USP Apparatus 2) at 75 rpm for class I, test and reference products, 
temperature will be adjusted to 37
◦
C ± 0.5 C .Twelve dosage units of each product test and 
reference were evaluated in the three media. Sample aliquots of 10 ml were taken manually with 
 syringes. Samples were withdrawn at specified time intervals (10, 15, 30, 45, and 60 min) and 
replaced with 10 ml of appropriate medium. With drawn samples were filtered using 0.45-μm 
Millipore Filters, then 5 ml taken after filtration by volumetric pipette (3ml taken when use HCL 
buffer solution, and 1ml taken in case of acetate and phosphate buffer, and diluted to 50 ml). A 
uv–visible spectrophotometer was used to analyze dissolved drug in dissolution testing. Scanning 
of wavelength done in each buffer, and spectrum recorded between 200---800nm, and percentage 
% of drug dissolved calculated. 
Buffers Preparation: 
Simulated gastric fluid (SGF), simulated intestinal fluid (SIF), and acetate buffer pH (4.5) were 
prepared according to instructions in USP test solution. All media were prepared without 
enzymes, as follow: 
a- Simulated Gastric Fluid (SGF) pH (1.2): 
To prepare hydrochloric acid 0.1N, 8.5 ml was taken from concentrated HCL (37%) and volume 
completed to 1000 ml by distilled water. 
b- Simulated Intestinal Fluid (SIF) pH (6.8): 
Potassium phosphate monobasic KH2PO4 0.2 M was prepared by dissolving 27.22 g in water, 
and volume diluted to 1000 ml by distilled water. Then sodium hydroxide 0.2 M prepared by 
dissolving 8g in water and volume diluted to 1000 ml by distilled water. 250 ml from Potassium 
phosphate monobasic KH2PO4 0.2 M was placed into 200 ml volumetric flask, also 112 ml 
taken from sodium hydroxide 0.2M and volume completed to 1000 ml with distilled water. 
c- Acetate Buffer pH (4.5): 
Firstly acetic acid 0.2N was prepared from concentrated acetic acid 99.93%. 116 ml was taken 
and diluted with distilled water. Then 2.99 g of sodium acetate (NaC2H3O2) taken, and placed in 
1000 ml volumetric flask,14ml from acetic acid was added and volume completed to 1000 ml by 
distilled water. 
Preparation of Standard Stock Solutions: 
Standard stock solutions of Metronidazole in HCL, phosphate and acetate buffers were prepared 
by dissolving 500 mg of standard in 100 ml volumetric flask using HCL, acetate and phosphate 
buffers as solvents to give concentration of 5 mg/ml, one ml taken by volumetric pipette in 100 
ml volumetric flask to give concentration of 50μg /ml, using 50 ml volumetric flask to give serial 
concentration of standard curve. 
Data Analysis: 
All dissolution data evaluated using Excel spread sheet, andthe results will be plotted for each 
brand. (Raimar, et.al, 2012).Average of % content of active pharmaceutical ingredient (API) 
dissolved in each media of 12 tablets will be taken and a plot of % of ( API) dissolved against 
time will be drawn to represent the dissolution profile .The dissolution profile for local brand 
will be compared to that of the reference drug. 
If they are similar the similarity factor, f2 equal to or more than 50.This means that they are 
equivalent, if it‟s less than 50 they are not equivalent. 
 
f1 = {[3t=1n | Rt - Tt| ]/[3t=1n Rt ]}C……… (1) 
 
f2 = 50 C log {[1+(1/n)3t=1n ( Rt - Tt )2 ] -0.5C 100}……… (2) 
 
Similarity factor f2 has been adopted by FDA and the European Agency for the Evaluation of 
Medicinal Products (EMEA) by the Committee for Proprietary Medicinal Products (CPMP) as a 
criterion to compare the similarity of two or more dissolution profiles. Similarity factor f2 is 
 included by the Centre for Drug Evaluation and Research (CDER) intheir guidelines such as 
guidance on dissolution testing of immediate release solid oral dosage forms (FDA, 1997) and 
guidance on Waiver of In-Vivo Bioavailability and Bioequivalence Studies for Immediate 
Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (FDA, 
2000).The area under the dissolution-time curve method was used in calculating the dissolution 
efficiency (DE), and this was calculated at 30 min .The higher the dissolution efficiency (DE) is, 
the better the release efficiency of the tablets‟ active ingredient, according to equation (3): 
 
 
………. (3) 
Where %D is the percentage dissolved at time t, % D (max) is the maximum dissolved at the 
final time T, and AUC(0-T )is the area under the curve from zero to time T( Anderson, et.al, 
1998). 
Correlation calculation will carried on using MINITAB14 specific statistical program. 
RESULTS: 
Correlation Results: 
In vitro - In vivo relationship Determination of Level A correlation. 
In vivo percent absorbed of reference product was calculated from equation (4): 
 
……………. (4) 
 
where, 
𝐴𝑡
𝐴0
denotes the fraction of drug absorbed at time t, Ct is the plasma drug concentration at 
time t, Kel is elimination rate constant, AUC0-t and AUC0-∞ are the area under the plasma 
concentration– time profile curve at time t and ∞ respectively. 
Then the values of percent of drug released were plotted against the percent of drug absorbed for 
reference products of Metronidazole using MINITAB14 analysis programto find out the 
relationship between data (correlation). 
Amount of drug released in the three different pH was plotted against amount of drug absorbed. 
DISCUSSION: 
A summary of the results of weight uniformity, hardness, friability, disintegration and assay are 
shown in Table 4. Weight uniformity may serve as a pointer to amount of the active 
pharmaceutical ingredient (API) contained in the formulation. All the brands complied with the 
compendial specification for weight uniformity.  
Hardness is referred to as non-compendial test. The hardness or crushing strength assesses the 
ability of dosage form to withstand handling without fracturing or chipping , It can also influence 
other parameters such as friability and disintegration. Hence, the dosage formsof all brands were 
satisfactory for hardness.  
 Friability test is used to evaluate the tablets resistance to abrasion. Friability is now included in 
the United States Pharmacopeia (USP, 1995) as a compendia test. The compendial specification 
for friability is less or equal to 1%. Friability for all brands of Metronidazole were  below 1%. 
Disintegration is the process of breaking of tablets in the liquid. Disintegration is a crucial step 
for immediate release dosage forms because the rate of disintegration affects the dissolution and 
subsequently the therapeutic efficacy of the medicine. A drug will be released rapidly as the 
dosage forms disintegrate. British Pharmacopeia specifies that uncoated tablets should 
disintegrate within 15 min and film coated tablet disintegrate within 30 min while USP 
specification for disintegration is 30 min forbothuncoated and film coated tablets. All the brands 
were complied with both BP and USP specifications for disintegration as maximum 
disintegration time.  
Potency is the average amount of the active ingredient present per tablet. All the brands complied 
both BP and USP specification, as USP specification is that the content of active ingredient 
should not be less than 90% and not more than 110% while BP specifies that the content should 
not be less than 95% and not more than 105%. 
The results of dissolution studies are graphically represented in the dissolution profile figures. 
All dissolution data are based on the actual drug content of the test dosage form as calculated 
from the assay results. All the Metronidazole brands released < 90% drug in acidic media (pH 
1.2) within 30 min, and PH (4.5). Amount released in phosphate buffer PH (6.8) were about 84% 
for reference drug and 91.4%,86.5% for test brands, This may be due to the pH depended 
solubility of metronidazole. 
Analysis of Dissolution Data: To compare the dissolution profiles of the brands, a model 
independent approach of difference factor f1 and similarity factor f2 were employed. Difference 
factor f1 is the percentage difference between two curves at each point and is a measurement of 
the relative error between the two curves. The similarity factor (f2) is a logarithmic reciprocal 
square root transformation of the sum of squared error and is a measurement of the similarity in 
the percent (%) dissolution between two curves. Two dissolution profiles to be considered 
similar and bioequivalent, f1 should be between 0 and 15 while f2 should be between 50 and 100 
(FDA, 1997). All the values for f2 and f1shown in tables 29 for metronidazole, as mentioned in 
previous tables, all brands f2 values were more than 50 and f1 values were less than 15. Which 
mean that all brands are equivalent with the innovator brand. 
In-vitro AUC in three PH (1.2),(4.5),(6.8)  for class I product were found three times in vivo  
bioequivalence AUC calculated before, which is acceptable result because the in-vitro 
dissolution studies were carried out in ideal conditions without any factors that could affect their 
performance, such as volunteers internal biological inconsistency. 
Dissolution efficiency (DE) was also employed to compare the drugrelease from various brands. 
The reference and the test product can said to beequivalent if the difference between their 
dissolutionefficiencies is within appropriate limits (± 10%, which isoften used) (Anderson NH, 
et, al 1998). Dissolution efficiency of all the brands (class I) differed by less than 10% from the 
innovator brand. So, we can say that all the brands are pharmaceutically equivalent with the 
innovator brand. 
In Vivo in Vitro Correlation Data Analysis: 
 As ivivc is a predictive mathematical model describing the relationship between variables (an in 
vitro property of a dosage form and a relevant in vivo response). 
According to MINITAM 14 statistical program, there was significant relationship between in 
vitro and in vivo data of reference metronidazole product, Correlation and distribution of data 
with correlation coefficient (r= 0.724, 0.837, 0.707), non linear relationship with p-value 
 (>0.05)= (0.167, 0.098 , 0.182), there is no out lines, no lake of fits at P-Values = 0.0040, 006, 
0.026. By analysis of variance (ANOVA) the data points have significant relationship with p-
value (> 0.05) for the three pH (1.2), (4.5), (6.8) respectively. 
Estimating the uncertainty in predicted correlation between in vitro and in vivo data was also 
performed. The interval is represented by the curved lines on either side of the regression line 
and gives an indication of the range within which the „true‟ line might lie. Note that the 
confidence interval is narrowest near the center (the point x, y) and less certain near the 
extremes. 
Using MINITAM 14 statistical program, there was significant relationship between in vitro and 
in vivo data of reference Atenolol product, Correlation and distribution of data with correlation 
coefficient (r= 0.798, 0.815, 0.967), non linear relationship with p-value (>0.05) = (0.106 , 0.93 , 
0.009), there is no out lines, no lake of fits at P-Values = 0.106, 0.040, 0.056 (>0.05) for the 
three pH (1.2,4.5,6.8) respectively. 
Estimating the uncertainty in predicted correlation between vitro and vivo data. The interval is 
represented by the curved lines on either side of the regression line and gives an indication of the 
range within which the „true‟ line might lie. Note that the confidence interval is narrowest near 
the center (the point x, y) and less certain near the extremes. 
By applying analysis of variance (ANOVA) for thedissolutiondata using MINITAB 14 we 
concluded that the test products are bioequivalent to reference products of metronidazole and 
atenolol and could be interchangeable.  
CONCLUSION: 
The bio waiver study has emphasized that pharmaceutical equivalence indicate that product have 
same drug molecule with approximately same pattern of dissolution release profile. By making 
fine turning in bioequivalent study we can reduce the time, cost, avoid Ethical, Ethnical 
consideration by unnecessary exposure of healthy subjects to medicines and finally to market the 
quality generic drug product. By applying level A in-vivo in-vitro correlation, we might 
concluded that there is no linear correlation between percent of drug released and percent of drug 
absorbed ,this may be due to uncontrollable gastric emptying rate for class one Metronidazole. 
Metronidazole is an immediate release formulations. As dissolution is not a rate-limiting step in 
IR products, the fraction of drug absorbed against the fraction of drug released profile would be 
non-linear type which was obtained in our present study. So it may be concluded that theIn vitro 
- In vivo correlation is well established and justified for reference formulation by level A 
correlation. 
By applying analysis of variance (ANOVA) for thedissolution data using MINITAB 14 we 
concluded that the test products are bioequivalent to reference products of metronidazole and 
could be interchangeable.  
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Table (1): Materials  
Expiry 
date 
Production 
date 
Batch 
number 
Manufacture Name 
2/2018 2/2013 3020142 AzalPharma Industries CO.LTD-
Sudan 
Metronidazole 
(standard) 
1/ 2019 4/ 2017 0155 Julphar- 
Gulf pharmaceutical industries, 
Ras Al Khaima,U.S.E 
Negazole500 mg 
 
8/2019 8/2017 170103 Blue Nile Pharmaceutical 
industries –Khartoum 
Nilozol 500 mg 
5/2018 5/2016 TMF076 Consolidated pharmaceutical 
industries 
Khartoum-sudan 
Metrodex 500mg 
 
Table (2) : Instruments 
Serial 
Number 
Name Production Country Instrument 
AE 260-5 SNR 
K 3L1360 
Metter instrument  AG Switzerland Sensitive balance 
0415021320 Tianjin guoming medical 
equipment 
 Automatic Tablet 
hardness tester 
123320.06  ad 
 
D-63150  Heusentamm Germany Friability tester 
 Erweka type DT 800 low 
head Heusrstarmm 
 
Germany 
Dissolution tester 
 erweka, TA120, 
,Heusrstarmm 
germany Disintegration tester 
 
 PH lab , 827, metrohm Switzerland PH Metter 
 
 UV min 1240, Shimadzu, Japan UV spectrophotometer 
 
 
 
 
 Table (3):Weight uniformity of atenolol tablets 
Number of tablets 
 
Deviation (%) Average weight of tablets 
Minimum 18 
Maximum 20 
± 10.0 
± 20.0 
Less than 80 mg 
Minimum 18 
Maximum 20 
± 7.5 
± 15.0 
80mg to 250mg 
Minimum 18 
Maximum 20 
± 5.0 
± 10.0 
More than 250mg 
 
Table (4): Quality control results of Metronidazole 
 
Assay 
% 
 
friability 
% 
 
Disintegration 
Time(min) 
 
Weight variation 
(RSD) 
 
Hardness 
(Kg/cm) 
 
Brands 
 
99.88 
 
0.01158 
 
8:27 
 
0.00386 
 
12.0 
 
Sample (A) 
 
98.75 
 
0.1843 
 
2:22 
 
0.0419 
 
12.5 
 
Sample (B) 
 
 
99.97 
 
0.0184 
 
3:20 
 
0.0243 
 
10.7 
 
Sample (C) 
 
 
 
 
 
Dissolution profile of Metronidazole in pH (1.2) 
 
 
 
 
10 15 30 45 60
niagazol 77.94 82.13 92.33 95.92 96.52
nilozol 82.13 92.33 94.72 96.52 98.32
metrodex 82.73 91.73 95.32 98.32 100.1
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Dissolution profile of metronidazole in pH (4.5) 
 
 
 
Dissolution profile of metronidazole in pH (6.8) 
 
 
 
Table (5) : F1 and f2 Values: 
6.8 4.5 1.2  Samples 
 F2 F1 F2 F1 F2 F1 
63 6 66 5 64 4 sample (B) 
66 4 58 7 63 5 sample (C ) 
 
 
 
 
 
 
 
 
 
10 15 30 45 60
niagazol 75.4 81.47 92.45 93.17 92.63
nilozol 81.29 86.15 90.89 94.96 99.46
metrodex 85.3 87.41 91.01 96.4 102.2
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10 15 30 45 60
samlpe (A) 74.28 79.92 86.51 90.1 92.27
samlpe (B) 79.68 84.17 91.37 95.14 97.12
samlpe (C) 83.27 84.35 83.99 89.39 90.11
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 Table (6): Dissolution efficiency for Metronidazole brands: 
6.8 4.5 1.2 Samples  
 Difference 
with 
reference 
AUC Difference 
with 
reference 
AUC Difference 
with 
reference 
AUC 
- 357.84 - 361.96 - 356.37 Sample (A) 
-3.19 355.03 11.82 350.14 -7.77 364.14 Sample (B) 
-12.73 364.51 16.11 345.85 -4.65 361.02 Sample (C ) 
 
 
 
Table (7): Relative dissolution efficiency of Metronidazole brands: 
6.8 4.5 1.2 PH 
100.91% 96.73% 102.18% Brand (B) 
103.62% 95.45% 101.30% Brand (C) 
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Metronidazole correlation in pH (1.2) 
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Metronidazole correlation in pH (4.5) 
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Metronidazole correlation in pH (6.8) 
 
 
 
 
